JP7602803B2 - Ｃｄ１４７キメラ抗原受容体および使用の方法 - Google Patents

Ｃｄ１４７キメラ抗原受容体および使用の方法 Download PDF

Info

Publication number
JP7602803B2
JP7602803B2 JP2021555228A JP2021555228A JP7602803B2 JP 7602803 B2 JP7602803 B2 JP 7602803B2 JP 2021555228 A JP2021555228 A JP 2021555228A JP 2021555228 A JP2021555228 A JP 2021555228A JP 7602803 B2 JP7602803 B2 JP 7602803B2
Authority
JP
Japan
Prior art keywords
cells
cell
car
nucleic acid
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021555228A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022525318A5 (https=
JP2022525318A (ja
JPWO2020190483A5 (https=
Inventor
ドンファン リウ，
Original Assignee
ラトガーズ、ザ ステイト ユニバーシティ オブ ニュージャージー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ラトガーズ、ザ ステイト ユニバーシティ オブ ニュージャージー filed Critical ラトガーズ、ザ ステイト ユニバーシティ オブ ニュージャージー
Publication of JP2022525318A publication Critical patent/JP2022525318A/ja
Publication of JP2022525318A5 publication Critical patent/JP2022525318A5/ja
Publication of JPWO2020190483A5 publication Critical patent/JPWO2020190483A5/ja
Priority to JP2024194375A priority Critical patent/JP2025013530A/ja
Application granted granted Critical
Publication of JP7602803B2 publication Critical patent/JP7602803B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/53—Liver
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
JP2021555228A 2019-03-15 2020-02-28 Ｃｄ１４７キメラ抗原受容体および使用の方法 Active JP7602803B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024194375A JP2025013530A (ja) 2019-03-15 2024-11-06 Ｃｄ１４７キメラ抗原受容体および使用の方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962819403P 2019-03-15 2019-03-15
US62/819,403 2019-03-15
PCT/US2020/020436 WO2020190483A1 (en) 2019-03-15 2020-02-28 Cd147 chimeric antigen receptors and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024194375A Division JP2025013530A (ja) 2019-03-15 2024-11-06 Ｃｄ１４７キメラ抗原受容体および使用の方法

Publications (4)

Publication Number Publication Date
JP2022525318A JP2022525318A (ja) 2022-05-12
JP2022525318A5 JP2022525318A5 (https=) 2023-02-24
JPWO2020190483A5 JPWO2020190483A5 (https=) 2023-02-24
JP7602803B2 true JP7602803B2 (ja) 2024-12-19

Family

ID=72520374

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021555228A Active JP7602803B2 (ja) 2019-03-15 2020-02-28 Ｃｄ１４７キメラ抗原受容体および使用の方法
JP2024194375A Withdrawn JP2025013530A (ja) 2019-03-15 2024-11-06 Ｃｄ１４７キメラ抗原受容体および使用の方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024194375A Withdrawn JP2025013530A (ja) 2019-03-15 2024-11-06 Ｃｄ１４７キメラ抗原受容体および使用の方法

Country Status (6)

Country Link
US (1) US20220152106A1 (https=)
EP (1) EP3938402A4 (https=)
JP (2) JP7602803B2 (https=)
CN (1) CN113853390B (https=)
CA (1) CA3132458A1 (https=)
WO (1) WO2020190483A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021396332A1 (en) * 2020-12-11 2023-06-22 Purdue Research Foundation Human chimeric antigen receptor neutrophils, compositions, kits and methods of use
WO2022138282A1 (ja) * 2020-12-22 2022-06-30 荒木技研工業株式会社 金属管の分岐部構造製造装置及び金属管の分岐部構造の製造方法
WO2023147019A2 (en) * 2022-01-28 2023-08-03 A2 Biotherapeutics, Inc. Compositions and methods for treating mesothelin positive cancers
WO2024220483A2 (en) * 2023-04-19 2024-10-24 Rutgers, The State University Of New Jersey Grp78 chimeric antigen receptors and combination therapies for treating cancer
WO2025105442A1 (ja) * 2023-11-15 2025-05-22 大塚製薬株式会社 キメラ抗原受容体

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012506369A (ja) 2008-09-29 2012-03-15 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ１４７抗体、方法及び使用
JP2018518972A (ja) 2015-06-26 2018-07-19 ユニバーシティ オブ サザン カリフォルニア 腫瘍特異的活性化のためのマスキングキメラ抗原受容体ｔ細胞
WO2018165619A1 (en) 2017-03-09 2018-09-13 Cytomx Therapeutics, Inc. Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995003828A1 (en) * 1993-08-02 1995-02-09 Houston Biotechnology Incorporated Single-chain immunotoxin compositions and methods for preventing secondary cataracts
ES2869972T3 (es) * 2015-01-26 2021-10-26 Cellectis Sistemas de receptores de antígenos quiméricos dirigidos por mAb para clasificar/agotar células inmunitarias genomanipuladas
US20200231652A1 (en) * 2015-08-31 2020-07-23 National Research Council Of Canada Tgf-b-receptor ectodomain fusion molecules and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012506369A (ja) 2008-09-29 2012-03-15 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ１４７抗体、方法及び使用
JP2018518972A (ja) 2015-06-26 2018-07-19 ユニバーシティ オブ サザン カリフォルニア 腫瘍特異的活性化のためのマスキングキメラ抗原受容体ｔ細胞
WO2018165619A1 (en) 2017-03-09 2018-09-13 Cytomx Therapeutics, Inc. Cd147 antibodies, activatable cd147 antibodies, and methods of making and use thereof

Also Published As

Publication number Publication date
JP2025013530A (ja) 2025-01-24
CN113853390A (zh) 2021-12-28
WO2020190483A1 (en) 2020-09-24
EP3938402A1 (en) 2022-01-19
JP2022525318A (ja) 2022-05-12
CA3132458A1 (en) 2020-09-24
EP3938402A4 (en) 2023-03-08
US20220152106A1 (en) 2022-05-19
CN113853390B (zh) 2025-04-25

Similar Documents

Publication Publication Date Title
JP7602803B2 (ja) Ｃｄ１４７キメラ抗原受容体および使用の方法
ES2967467T3 (es) Combinación de una terapia celular y un compuesto inmunomodulador
TWI790213B (zh) 用於使用融合蛋白之tcr重編程的組合物及方法
ES2959953T3 (es) Métodos para producir composiciones celulares genéticamente modificadas y composiciones relacionadas
KR20200108278A (ko) 조작된 ｔ 세포의 조성물을 제조하는 방법
JP2021525509A (ja) 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化
KR20200099132A (ko) 조작된 세포의 치료적 조성물을 생성하기 위한 프로세스
JP2020507605A (ja) Ｂｃｍａ関連癌および自己免疫疾患の治療のための併用療法
WO2020010110A1 (en) Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof
CN110177803A (zh) 用于使用融合蛋白进行tcr重新编程的组合物和方法
KR20210118426A (ko) 양자 세포 요법을 위한 표적화된 공자극을 제공하는 수용체
TW201706295A (zh) 靶向血液惡性腫瘤之嵌合抗原受體（ｃａｒ），其組合物及使用方法
KR20210045418A (ko) 크렙스 사이클을 조정하는 트랜스 대사 분자와 조합된 키메라 항원 수용체 폴리펩타이드 및 이의 치료적 용도
EP3938387A1 (en) Chimeric adaptor and kinase signaling proteins and their use in immunotherapy
US20230322923A1 (en) Methods and compositions relating to ex vivo culture and modulation of t cells
EP3487877A1 (en) Use of antibody-coupled t cell receptor (actr) with multiple anti-cancer antibodies in cancer treatment
EP4408982A1 (en) Chimeric receptor polypeptides in combination with trans metabolism molecules that re-direct glucose metabolites out of the glycolysis pathway and therapeutic uses thereof
KR20230020421A (ko) Cd70 특이적 융합 단백질을 사용하는 tcr 재프로그래밍을 위한 조성물 및 방법
JP7379164B2 (ja) 細胞療法に関連する毒性に関する製造物品および方法
US12605446B2 (en) PSMA-targeted immunotherapies for cancers
JP7837864B2 (ja) Ｔ細胞療法と（ｓ）－３－［４－（４－モルホリン－４－イルメチル－ベンジルオキシ）－１－オキソ－１，３－ジヒドロ－イソインドール－２－イル］－ピペリジン－２，６－ジオンとの併用
JP7531603B2 (ja) Ｃｄ２８ｈドメイン含有キメラ抗原受容体および使用方法
WO2025134168A1 (en) Genetically modified immune cells for the treatment of tumors and autoimmune diseases
US20240189351A1 (en) Il-13ra2 chimeric antigen receptors and methods of use
WO2025016450A1 (en) Combination of cldn18.2 and gucy2c targeted antagonist therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240415

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240618

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241106

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241115

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241202

R150 Certificate of patent or registration of utility model

Ref document number: 7602803

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150